Genfit S.A. (GNFT)

NASDAQ: GNFT · IEX Real-Time Price · USD
3.42
0.07 (2.09%)
May 18, 2022 4:00 PM EDT - Market closed
Market Cap170.37M
Revenue (ttm)97.25M
Net Income (ttm)76.43M
Shares Out49.82M
EPS (ttm)1.28
PE Ratio2.67
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,033
Open3.43
Previous Close3.35
Day's Range3.37 - 3.48
52-Week Range3.01 - 6.38
Beta1.24
AnalystsBuy
Price Target9.43 (+175.7%)
Earnings DateJul 7, 2022

About GNFT

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was...

IndustryBiotechnology
IPO DateMar 27, 2019
CEOPascal Prigent
Employees130
Stock ExchangeNASDAQ
Ticker SymbolGNFT
Full Company Profile

Financial Performance

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 14 analysts, the average rating for GNFT stock is "Buy." The 12-month stock price forecast is 9.43, which is an increase of 175.73% from the latest price.

Price Target
$9.43
(175.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)

Lille, France; Cambridge, M A ; May 1 1 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseas...

1 week ago - GlobeNewsWire

GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Ava...

Lille, France; Cambridge, M A ; April 29 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver disea...

2 weeks ago - GlobeNewsWire

GENFIT Annual Combined General Meeting of May 25, 2022 — Availability of Preparatory Documents

Lille, France; Cambridge, M A ; April 20 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver disea...

4 weeks ago - GlobeNewsWire

What Makes GENFIT S.A. Unsponsored ADR (GNFT) a New Buy Stock

GENFIT S.A. Unsponsored ADR (GNFT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 month ago - Zacks Investment Research

GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate Update

Lille, France; Cambridge, M A ; April 7 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseas...

1 month ago - GlobeNewsWire

GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021

Lille, France; Cambridge , M A ; February 2 6 , 202 1 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver ...

2 months ago - GlobeNewsWire

GENFIT: 2022 Financial Calendar

Lille, France; Cambridge, MA; January 24, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver disease...

3 months ago - GlobeNewsWire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille, France; Cambridge, M A ; January 21 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic li...

3 months ago - GlobeNewsWire

Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 78.9% upside potential for GENFIT S.A. Unsponsored ADR (GNFT).

4 months ago - Zacks Investment Research

How Much Upside is Left in GENFIT S.A. Unsponsored ADR (GNFT)?

The mean of analysts' price targets for GENFIT S.A. Unsponsored ADR (GNFT) points to a 59.9% upside in the stock.

4 months ago - Zacks Investment Research

These Biotech Penny Stocks Exploded Today, Here's Why

Which biotech penny stocks are you watching right now? The post These Biotech Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:BLPHXFOR
5 months ago - PennyStocks

GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Genfit as Shares Go Gangbusters

Genfit (GNFT) stock is rocketing higher on Friday after the company signed an exclusive licensing agreement with Ipsen (IPSEY). The post GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Gen...

5 months ago - InvestorPlace

Why Genfit Shares Are Rising

Genfit SA (NASDAQ: GNFT) shares are trading higher after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor. David Loew, Chief Executive Officer, Ipsen, said, "Today's an...

5 months ago - Benzinga

Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful

Ipsen SA (OTC: IPSEY) has entered into a long-term strategic partnership to develop, manufacture, and commercialize and Genfit SA's (NASDAQ: GNFT) elafibranor for Primary Biliary Cholangitis (PBC).  Und...

5 months ago - Benzinga

On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset

Lille, France; Cambridge, M A ; December 1 7 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic l...

5 months ago - GlobeNewsWire

GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Pri...

GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor , a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

5 months ago - GlobeNewsWire

Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Bil...

PARIS--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) have entered in...

5 months ago - Business Wire

GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology's Unique Performance in Identifying Patients with “at-risk” NASH

Lille, France; Cambridge, M A ; November 18 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic li...

6 months ago - GlobeNewsWire

GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of i...

Lille, France; Cambridge, M A ; November 09 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic li...

6 months ago - GlobeNewsWire

GENFIT: Third Quarter 2021 Financial Information

Lille, France; Cambridge, M A ; November 8 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liv...

6 months ago - GlobeNewsWire

New Clinical Data on GENFIT's Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting®

Lille, France; Cambridge, MA; November 0 2 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liv...

6 months ago - GlobeNewsWire

GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update

GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update

7 months ago - GlobeNewsWire

GENFIT: June 30, 2021 Annual Shareholders Meeting results

L ille (France) ; C ambridge ( M assachusetts, United States) — June 30 , 202 1 — GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients ...

10 months ago - GlobeNewsWire

GENFIT obtains non-dilutive financing of €11 million in the form of a State Guaranteed Loan

Lille, France; Cambridge, M A ; June 24 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases...

10 months ago - GlobeNewsWire

GENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the A...

Lille, France; Cambridge, M A ; June 2 3 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver disease...

10 months ago - GlobeNewsWire